In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

An AI researcher and former teacher shares insights on how new technologies will affect math instruction and learning.

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Professors from NYU and the University of British Columbia have resolved the Kakeya set conjecture in three dimensions.

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Pure mathematics uses mathematics to explore abstract ideas, mathematics that does not necessarily describe a real physical system. This can include developing the fundamental tools used by ...

Gemini 2.5 Pro is a multimodal, reasoning model that outperforms competitors from OpenAI, Anthropic, and DeepSeek on key ...

The latest trading session saw Vertex Pharmaceuticals (VRTX) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of ...